Results 111 to 120 of about 18,762 (211)

JAK inhibitors and menstrual cycle alterations: insights from a case series of 16 female patients

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Luciano Ibba, Luigi Gargiulo, Matteo Bianco, Sara Di Giulio, Ruggero Cascio Ingurgio, Angela Alfano, Carlo A. Vignoli, Mario Valenti, Paola Facheris, Chiara Perugini, Alessandra Narcisi, Antonio Costanzo   +11 more
wiley   +1 more source

Periodontitis and rheumatoid arthritis—Global efforts to untangle two complex diseases

Periodontology 2000, EarlyView.
Abstract Understanding the impact of oral health on rheumatoid arthritis (RA) will inform how best to manage patients with both periodontitis and RA. This review seeks to provide an update on interventional and mechanistic investigations, including a brief summary of European Research programs investigating the link between periodontitis and RA. Recent
Isabel Lopez‐Oliva, Jennifer Malcolm, Shauna Culshaw   +2 more
wiley   +1 more source

Use Patterns of Novel Janus Kinase Inhibitors After the First Safety Alerts: A Nationwide Register‐Based Time Series Analysis

Pharmacoepidemiology and Drug Safety, Volume 35, Issue 6, June 2026.
ABSTRACT Purpose Janus kinase inhibitors (JAKi) are medicines used to treat inflammatory rheumatic musculoskeletal diseases (IRMDs) and inflammatory bowel diseases (IBDs). In Europe, JAKis received marketing authorisation in 2017 for rheumatoid arthritis.
Jarno Rutanen, Pekka Heino, Kati Sarnola, Terhi Kurko   +3 more
wiley   +1 more source

Repurposed Medicines for Viruses With Epidemic or Pandemic Potential: A Horizon Scan

Pharmacology Research &Perspectives, Volume 14, Issue 3, June 2026.
ABSTRACT Viruses such as Ebola, Marburg, influenza, mpox, MERS‐CoV, SARS‐CoV, and SARS‐CoV‐2 may be considered pathogens of epidemic or pandemic concern. Developing novel antiviral medicines can be time‐consuming and resource intensive. Repurposing existing medicines with known or potential antiviral activity offers a faster, cost‐effective strategy to
Sola Akinbolade, Rhiannon Potter, Alex Inskip, Jane Nesworthy, Kirsti Brock, Gill Norman   +5 more
wiley   +1 more source

Longer-term safety and efficacy of baricitinib for atopic dermatitis in pediatric patients 2 to <18 years old: a randomized clinical trial of extended treatment to 3.6 years

Journal of Dermatological Treatment
Background Baricitinib, an oral selective Janus kinase inhibitor, improved clinical signs and symptoms of moderate-to-severe atopic dermatitis (AD) at week 16 in the phase 3 pediatric study BREEZE-AD-PEDS.Objective To assess longer-term efficacy and ...
Andreas Wollenberg, Masanori Ikeda, Chia-Yu Chu, Lawrence F. Eichenfield, Marieke M. B. Seyger, Apurva Prakash, Robinette Angle, Danting Zhu, Marco Pontes, Amy S. Paller   +9 more
doaj   +1 more source

Toward Personalized Medicine in Type 1 Diabetes: Understanding How Patient Heterogeneity Influences Therapeutic Efficacy

Diabetes, Obesity and Metabolism, Volume 28, Issue 6, Page 4529-4545, June 2026.
ABSTRACT Pharmacologic interventions for type 1 diabetes (T1D) have advanced significantly in recent years with the advent of the first FDA approved therapy teplizumab for delaying symptomatic disease onset in 2022. Despite this progress, major hurdles remain in moving toward personalized medicine approaches for T1D.
Jasmine Pipella, Peter J. Thompson
wiley   +1 more source

Direct Effects of the Janus Kinase Inhibitor Baricitinib on Sensory Neurons [PDF]

Therapeutically, the Janus kinase (Jak) 1/Jak2 inhibitor baricitinib reduces the pathology of rheumatoid arthritis and may also reduce pain. Here, we investigated whether baricitinib directly affects joint nociceptors.
Eitner, Annett, König, Christian, Natura, Gabriel, Richter, Frank, Schaible, Hans-Georg, Vazquez, Enrique   +5 more
core   +1 more source

Baricitinib for refractory Takayasu arteritis: a prospective cohort study in a tertiary referral centre

RMD Open
Objective To investigate the treatment efficacy and safety of baricitinib in patients with refractory Takayasu arteritis (TAK).Methods We performed a prospective cohort study in which baricitinib 4 mg daily was prescribed to patients with refractory TAK,
Jing Li, Li Wang, Li Zhang, Xiaofeng Zeng, Xinping Tian, Shangyi Jin, YunJiao Yang, Ziyue Zhou, Chenglong Fang   +8 more
doaj   +1 more source

Oral lichenoid lesions in CTLA‐4 haploinsufficiency: Targeting IFN‐γ‐driven mucosal immunopathology

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Chen Wang, Laurie Brenchley, Teresa Greenwell‐Wild, Vasileios Ionas Theofilou, Timothy G. Myers, Chi A. Ma, Katherine Howe, Stefania Pittaluga, Steven M. Holland, Niki M. Moutsopoulos, David Fraser, Gulbu Uzel   +11 more
wiley   +1 more source

Successful Treatment of Immune Checkpoint Inhibitor‐Induced Myocarditis, Myositis, and Myasthenia Overlap Syndrome With Baricitinib and Abatacept

Clinical Case Reports, Volume 14, Issue 5, May 2026.
ABSTRACT Immune checkpoint inhibitor (ICI) therapies are known to cause immune‐related adverse events (irAEs), including life‐threatening myocarditis, myositis, and myasthenia (MMM) overlap syndrome. Current literature lacks established therapeutic guidelines for effective management with steroid‐sparing agents.
Zeinab Alnahas, Sujata Sarkar, Oishi Roychoudhury, Ernest Algabre   +3 more
wiley   +1 more source